Literature DB >> 30698262

Protocol for hypertensive individuals assisted in Basic Health Care.

Rosimery Cruz de Oliveira Dantas1, Angelo Giuseppe Roncalli2.   

Abstract

Hypertension has low control rate in Brazil and around the World, resulting in social and medical costs; thus there is the need to apply control strategies. This study aimed to create and validate a protocol for consultation and monitoring of hypertensive patients attended in primary health care. It is constituted a methodological research which uses the Delphi method for content validation. The analysis of the protocol by experts was performed in three cycles, using a scale that was not important to extremely important, with a graduation from 1 to 5. The analysis was performed by the Likert scale, percentage of agreement, content validation index, Pearson correlation. The percentage of agreement was 96%. The CVI of 0.98. The Likert scale scored items, at least, as very important. The Pearson correlation was positive for all items ranging from moderate to strong. The protocol is composed of 53 items, divided into seven dimensions. It was concluded that the protocol enables more expressive and systematics monitoring of hypertensive patients and it identifies social and individual conditions that contribute to high blood pressure, so it may be used to guide the consultation, encouraging dialogue between the professional and patient and effective recording of care.

Entities:  

Mesh:

Year:  2019        PMID: 30698262     DOI: 10.1590/1413-81232018241.35362016

Source DB:  PubMed          Journal:  Cien Saude Colet        ISSN: 1413-8123


  1 in total

1.  Effects of using a mobile health application on the health conditions of patients with arterial hypertension: A pilot trial in the context of Brazil's Family Health Strategy.

Authors:  Raquel Debon; Ericles Andrei Bellei; Daiana Biduski; Simiane Salete Volpi; Ana Luisa Sant'Anna Alves; Marilene Rodrigues Portella; Ana Carolina Bertoletti De Marchi
Journal:  Sci Rep       Date:  2020-04-07       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.